Clinical characteristics, demographics, and outcomes in hormone-receptor (HR plus ) positive metastatic breast cancer (MBC) patients treated with palbociclib.

被引：0
|
作者：
Landry, Chrystal Ann
Dimitrova, Maya
Ru, Meng
Teplinsky, Eleonora
Tiersten, Amy
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY USA
[2] Valley Hlth Syst, Paramus, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e13027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13027
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real world clinical outcomes of palbociclib in hormone receptor positive (HR plus ) metastatic breast cancer (MBC) patients.
    Eziokwu, Akaolisa Samuel
    Varella, Leticia
    Kruse, Megan Lynn
    Jia, Xuefei
    Moore, Halle C. F.
    Budd, George Thomas
    Abraham, Jame
    Montero, Alberto J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Impact of early dose reduction of palbociclib on clinical outcomes in patients with hormone-receptor positive metastatic breast cancer
    Moftakhar, Bahar
    Lekkala, Manidhar Reddy
    Strawderman, Myla
    Smith, Tae C.
    Meacham, Philip
    Fitzgerald, Bryan
    Dhakal, Ajay
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [3] Treatment of HER2-positive (HER2+) hormone-receptor positive (HR plus ) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant
    Escriva-De-Romani, Santiago
    Alba, Emilio
    Rodriguez-Lescure, Alvaro
    Hurvitz, Sara
    Cejalvo, Juan Miguel
    Gion, Maria
    Ferrario, Cristiano
    Borrego, Manuel Ruiz
    Pezo, Rossanna C.
    Hamilton, Erika
    Webster, Marc
    Pluard, Timothy
    Beeram, Muralidhar
    Rodriguez, Begona Jimenez
    Linden, Hannah
    Saura, Cristina
    Omidpanah, Adam
    Harvey, Phoebe
    Savard, Marie-France
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [4] Genomic testing and uptake of alteration-targeted therapies among patients with hormone-receptor positive (HR plus ) metastatic breast cancer (MBC)
    Mahadevia, Himil
    Chandra, Simran
    Gosch, Kensey
    Khamees, Ibrahim
    Sharma, Parth
    Gast, Kelly C.
    Pluard, Timothy J.
    Hensing, Whitney L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2-breast cancer
    Wander, S. A.
    Spring, L. M.
    Stein, C. R.
    Yuen, M.
    Zangardi, M.
    O'Shaughnessy, J.
    Bardia, A.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [6] AKT1 alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR plus ) metastatic breast cancer (MBC): Clinical and functional implications
    Wander, Seth
    Mao, Pingping
    Lloyd, Maxwell
    Kowalski, Kailey
    Johnson, Gabriela N.
    Malvarosa, Giuliana
    Moy, Beverly
    Ellisen, Leif W.
    Iafrate, John
    Wagle, Nikhil
    Bardia, Aditya
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [7] Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR plus ) metastatic breast cancer (MBC).
    Tan, Antoinette R.
    Wong, Serena Tsan-Lai
    Warren, Robert D.
    Eng-Wong, Jennifer
    Liu, Minetta C.
    Zelnak, Amelia Bruce
    Lin, Yong
    Shih, Weichung
    Ganesan, Shridar
    Grana, Generosa
    Isaacs, Claudine
    Toppmeyer, Deborah
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Real-world experience of exemestane-everolimus (EXE-EVE) in elderly patients with hormone-receptor positive (HR plus ) metastatic breast cancer (MBC).
    Redana, Stefania
    Papadimitraki, Elisavet
    Okonji, David Odhiambo
    Khabra, Komel
    Thanopoulou, Eirini
    Chiramel, Jaseela
    Papanastasopoulos, Panagiotis
    Wardley, Andrew M.
    Hogg, Martin S.
    Howell, Sacha Jon
    Zucchini, Giorgia
    Kenny, Laura M.
    Ring, Alistair E.
    Johnston, Stephen R. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] General Characteristics, Patterns of Relapse and Treatment Outcomes of Patients with HER2 Amplified Metastatic Breast Cancer (MBC) who are Hormone Receptor Positive (HR plus ) Versus Hormone Receptor Negative (HR-)
    Dumbrava, Monica I.
    De Boer, Richard
    Lok, Sheau
    Gibbs, Peter
    Greenberg, Sally
    Pellegrini, Laura
    Yip, Desmond
    Malik, Laeeq
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 119 - 120
  • [10] registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Tripathy, D.
    Kaufman, P.
    Brufsky, A.
    Mayer, M.
    Yood, M.
    Wang, L.
    Brammer, M.
    Yardley, D.
    Tan-Chiu, E.
    Rugo, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345